Showing results (1-10 of 155) with videos related to
Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 9, 2005
Antimicrobial safety: focus on fluoroquinolonesRobert C Owens, Paul G AmbrosePharmacotherapy|May 16, 2002
Torsades de pointes associated with fluoroquinolonesRobert C Owens, Paul G AmbroseDiagnostic Microbiology and Infectious Disease|February 13, 2007
Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic eraRobert C Owens, Paul G AmbroseDiagnostic Microbiology and Infectious Disease|January 5, 2005
Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniaeRobert C Owens, Sujata M Bhavnani, Paul G AmbroseInfectious Disease Clinics of North America|January 9, 2004
Clinical pharmacodynamics of quinolonesPaul G Ambrose, Sujata M Bhavnani, Robert C OwensThe Journal of Antimicrobial Chemotherapy|February 28, 2002
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepimePaul G Ambrose, Robert C Owens, Michael J Garvey, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2008
Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study designPaul G AmbroseTreatments in Respiratory Medicine|April 23, 2005
Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpointsPaul G AmbroseCurrent Opinion in Pharmacology|July 9, 2017
Antibacterial drug development program successes and failures: a pharmacometric explanationPaul G AmbrosePharmacotherapy|March 2, 2006
Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacistsPaul G AmbrosePageof 16